Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020

Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017

Mitsuru MukaigawaraComments to Author , Masashi Narita, Soichi Shiiki, Yoshihiro Takayama, Shunichi Takakura, and Tomokazu Kishaba
Author affiliations: Harvard Kennedy School, Cambridge, Massachusetts, USA (M. Mukaigawara); Okinawa Chubu Hospital, Uruma, Okinawa, Japan (M. Mukaigawara, M. Narita, S. Shiiki, Y. Takayama, S. Takakura, T. Kishaba)

Main Article

Table 4

Involvement of larvae and enteric organisms in disseminated strongyloidiasis reported in previous studies*

Characteristic Dissemination Occult dissemination with meningitis/enteric organisms Occult dissemination with culture-negative suppurative meningitis
Involvement of larvae
Confirmed (rhabditiform and filariform larvae)
Confirmed (rhabditiform larvae)
Confirmed (rhabditiform larvae)
Involvement of enteric organisms Confirmed Confirmed Not detected

*References 11, 14, and 15.

Main Article

  1. Olsen  A, van Lieshout  L, Marti  H, Polderman  T, Polman  K, Steinmann  P, et al. Strongyloidiasis—the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg. 2009;103:96772. DOIPubMedGoogle Scholar
  2. Igra-Siegman  Y, Kapila  R, Sen  P, Kaminski  ZC, Louria  DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981;3:397407. DOIPubMedGoogle Scholar
  3. Fardet  L, Généreau  T, Poirot  JL, Guidet  B, Kettaneh  A, Cabane  J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54:1827. DOIPubMedGoogle Scholar
  4. Marty  FM. Strongyloides hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. Transpl Infect Dis. 2009;11:979. DOIPubMedGoogle Scholar
  5. Sánchez  PR, Guzman  AP, Guillen  SM, Adell  RI, Estruch  AM, Gonzalo  IN, et al. Endemic strongyloidiasis on the Spanish Mediterranean coast. QJM. 2001;94:35763. DOIPubMedGoogle Scholar
  6. Keiser  PB, Nutman  TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17:20817. DOIPubMedGoogle Scholar
  7. US Centers for Disease Control and Prevention. Parasites: Strongyloides. Biology [cited 2019 Feb 1].
  8. Mansfield  LS, Alavi  A, Wortman  JA, Schad  GA. Gamma camera scintigraphy for direct visualization of larval migration in Strongyloides stercoralis-infected dogs. Am J Trop Med Hyg. 1995;52:23640. DOIPubMedGoogle Scholar
  9. Pukkila-Worley  R, Nardi  V, Branda  JA. Case records of the Massachusetts General Hospital. Case 28-2014. A 39-year-old man with a rash, headache, fever, nausea, and photophobia. N Engl J Med. 2014;371:105160. DOIPubMedGoogle Scholar
  10. Kishaba  T. Disseminated strongyloidiasis. In: Shiroma Y, Sato Y, editors. Strongyloides stercoralis and strongyloidiasis in Japan [in Japanese]. Fukuoka (Japan): Kyushu University Press; 1997. p. 55–78.
  11. Kishaba  T. Strongyloidiasis and infections due to enteric organisms: sepsis, pneumonia and meningitis caused by Gram-negative bacteria associated with disseminated strongyloidiasis [in Japanese]. Infection. 1982;12:180.
  12. Jain  AK, Agarwal  SK, el-Sadr  W. Streptococcus bovis bacteremia and meningitis associated with Strongyloides stercoralis colitis in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1994;18:2534. DOIPubMedGoogle Scholar
  13. Chu  E, Whitlock  WL, Dietrich  RA. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest. 1990;97:14757. DOIPubMedGoogle Scholar
  14. Kishaba  T, Uchihara  T, Ueno  K, Goeku  C, Shimabukuro  Y. Gram-negative rod meningitis probably caused by occult disseminated strongyloidiasis [in Japanese]. Okinawa Medical Journal. 1985;22:3.
  15. Kishaba  T, Suginohara  K, Tamaki  K, Miyara  Y, Endo  K, Taira  Y, et al. Culture negative suppurative meningitis probably caused by occult disseminated strongyloidiasis [in Japanese]. Okinawa Medical Journal. 1989;26:219.
  16. Mukaigawara  M, Nakayama  I, Gibo  K. Strongyloidiasis and culture-negative suppurative meningitis, Japan, 1993–2015. Emerg Infect Dis. 2018;24:237880. DOIPubMedGoogle Scholar
  17. Sasaki  Y, Taniguchi  T, Kinjo  M, McGill  RL, McGill  AT, Tsuha  S, et al. Meningitis associated with strongyloidiasis in an area endemic for strongyloidiasis and human T-lymphotropic virus-1: a single-center experience in Japan between 1990 and 2010. Infection. 2013;41:118993. DOIPubMedGoogle Scholar
  18. Shimasaki  T, Chung  H, Shiiki  S. Five cases of recurrent meningitis associated with chronic strongyloidiasis. Am J Trop Med Hyg. 2015;92:6014. DOIPubMedGoogle Scholar
  19. Toma  H, Shimabukuro  I, Kobayashi  J, Tasaki  T, Takara  M, Sato  Y. Community control studies on Strongyloides infection in a model island of Okinawa, Japan. Southeast Asian J Trop Med Public Health. 2000;31:3837.PubMedGoogle Scholar
  20. Sagara  Y, Iwanaga  M, Morita  M, Sagara  Y, Nakamura  H, Hirayama  H, et al. Fine-scale geographic clustering pattern of human T-cell leukemia virus type 1 infection among blood donors in Kyushu-Okinawa, Japan. J Med Virol. 2018;90:165865. DOIPubMedGoogle Scholar
  21. Cresci  GA, Bawden  E. Gut microbiome: what we do and don’t know. Nutr Clin Pract. 2015;30:73446. DOIPubMedGoogle Scholar
  22. Scowden  EB, Schaffner  W, Stone  WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore). 1978;57:52744. DOIPubMedGoogle Scholar
  23. Tomori  M, Mukaigawara  M, Narita  M. Acute esophageal necrosis associated with Strongyloides stercoralis hyperinfection. Am J Trop Med Hyg. 2019;100:10378. DOIPubMedGoogle Scholar
  24. Geri  G, Rabbat  A, Mayaux  J, Zafrani  L, Chalumeau-Lemoine  L, Guidet  B, et al. Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature. Infection. 2015;43:6918. DOIPubMedGoogle Scholar
  25. Tanaka  T, Hirata  T, Parrott  G, Higashiarakawa  M, Kinjo  T, Kinjo  T, et al. Relationship among Strongyloides stercoralis infection, human T-cell lymphotropic virus type 1 infection, and cancer: a 24-year cohort inpatient study in Okinawa, Japan. Am J Trop Med Hyg. 2016;94:36570. DOIPubMedGoogle Scholar
  26. Schär  F, Trostdorf  U, Giardina  F, Khieu  V, Muth  S, Marti  H, et al. Strongyloides stercoralis: global distribution and risk factors. PLoS Negl Trop Dis. 2013;7:e2288. DOIPubMedGoogle Scholar
  27. Teixeira  MC, Pacheco  FT, Souza  JN, Silva  ML, Inês  EJ, Soares  NM. Strongyloides stercoralis infection in alcoholic patients. BioMed Res Int. 2016;2016:4872473. DOIPubMedGoogle Scholar
  28. de Oliveira  LC, Ribeiro  CT, Mendes  DM, Oliveira  TC, Costa-Cruz  JM. Frequency of Strongyloides stercoralis infection in alcoholics. Mem Inst Oswaldo Cruz. 2002;97:11921. DOIPubMedGoogle Scholar
  29. Gotuzzo  E, Terashima  A, Alvarez  H, Tello  R, Infante  R, Watts  DM, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg. 1999;60:1469. DOIPubMedGoogle Scholar
  30. Hays  R, Esterman  A, McDermott  R. Type 2 diabetes mellitus is associated with Strongyloides stercoralis treatment failure in Australian aboriginals. PLoS Negl Trop Dis. 2015;9:e0003976. DOIPubMedGoogle Scholar
  31. Henriquez-Camacho  C, Gotuzzo  E, Echevarria  J, White  AC Jr, Terashima  A, Samalvides  F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016; (1):CD007745. DOIPubMedGoogle Scholar
  32. Zaha  O, Hirata  T, Kinjo  F, Saito  A, Fukuhara  H. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother. 2002;8:948. DOIPubMedGoogle Scholar
  33. Mejia  R, Nutman  TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis. 2012;25:45863. DOIPubMedGoogle Scholar
  34. Tarr  PE, Miele  PS, Peregoy  KS, Smith  MA, Neva  FA, Lucey  DR. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg. 2003;68:4535. DOIPubMedGoogle Scholar
  35. Barrett  J, Broderick  C, Soulsby  H, Wade  P, Newsholme  W. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother. 2016;71:2205. DOIPubMedGoogle Scholar
  36. Marty  FM, Lowry  CM, Rodriguez  M, Milner  DA, Pieciak  WS, Sinha  A, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis. 2005;41:e58. DOIPubMedGoogle Scholar
  37. Pornsuriyasak  P, Niticharoenpong  K, Sakapibunnan  A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health. 2004;35:5314.PubMedGoogle Scholar
  38. Kishimoto  K, Hokama  A, Hirata  T, Ihama  Y, Nakamoto  M, Kinjo  N, et al. Endoscopic and histopathological study on the duodenum of Strongyloides stercoralis hyperinfection. World J Gastroenterol. 2008;14:176873. DOIPubMedGoogle Scholar

Main Article

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.